The FDA recently approved a brain-stimulation headset from Swedish company Flow Neuroscience as a first-line treatment for depression. Utilizing transcranial direct-current stimulation (tDCS), the device delivers a weak electric current to the brain to help neurons fire more effectively. Unlike the more intensive electroconvulsive therapy (ECT), which triggers seizures and can cause memory loss, tDCS is designed for home use and typically results in only minor, temporary side effects like skin irritation or headaches.
The approval marks a significant shift in psychiatry, offering an alternative or supplement to traditional antidepressants like SSRIs. While many treatments focus on chemical imbalances, neuromodulation views depression as a matter of impaired neural connectivity. Proponents argue that electricity is the “lingua franca” of the brain, and using a device to “tickle neurons” could help patients move past old mental patterns. In some cases, clinicians have used the headset to help patients avoid additional medications or taper off existing ones.
Despite the milestone, the technology remains in its early stages with varying clinical results. While a recent trial showed that 45% of participants achieved full remission using the device, the FDA noted a “moderate level of uncertainty” regarding its benefits compared to placebos. Researchers are now looking to refine the technology through personalized brain mapping and higher voltages. For patients like Sophie Davies, who used the device alongside medication, the therapy provided a much-needed sense of clarity and emotional recovery during a mental health crisis.
To read the entire article on The New York Times website, click here.